步长制药：子公司撤回恩格列净片药品上市许可注册申请

Core Viewpoint - The company, Bichang Pharmaceutical, announced the withdrawal of its drug registration application for "Empagliflozin Tablets" due to the need for further improvement of the application materials, but this does not signify the termination of the project [1] Group 1 - Bichang Pharmaceutical's wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., received a notice from the National Medical Products Administration regarding the termination of the drug registration application for "Empagliflozin Tablets" [1] - "Empagliflozin Tablets" are intended for the treatment of type 2 diabetes [1] - The company plans to resubmit the drug registration application after completing the necessary research [1]